Citigroup Inc. assumed coverage on shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) in a research report released on Tuesday. The brokerage issued a market perform rating and a $55.00 price target on the stock. The analysts noted that the move was a valuation call.

NBIX has been the topic of a number of other reports. Jefferies Group reissued a buy rating and issued a $61.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, September 23rd. BMO Capital Markets reaffirmed an outperform rating and set a $66.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 13th. Piper Jaffray Cos. reiterated an overweight rating and set a $96.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, September 22nd. Robert W. Baird reiterated an outperform rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday, August 30th. Finally, Leerink Swann reiterated an outperform rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, October 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $66.92.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) traded up 0.90% during midday trading on Tuesday, reaching $49.49. The company had a trading volume of 117,511 shares. The firm has a 50-day moving average price of $46.84 and a 200-day moving average price of $48.09. Neurocrine Biosciences has a 52 week low of $31.25 and a 52 week high of $58.46. The company’s market capitalization is $4.30 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.14. During the same quarter in the prior year, the company posted ($0.40) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. Analysts expect that Neurocrine Biosciences will post ($1.68) EPS for the current fiscal year.

In related news, insider Malcolm Lloyd-Smith sold 9,000 shares of the business’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $50.00, for a total transaction of $450,000.00. Following the transaction, the insider now directly owns 9,000 shares in the company, valued at $450,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Flint Obrien sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $52.84, for a total transaction of $1,321,000.00. Following the transaction, the insider now owns 30,044 shares in the company, valued at $1,587,524.96. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NBIX. Alps Advisors Inc. raised its position in Neurocrine Biosciences by 25.2% in the second quarter. Alps Advisors Inc. now owns 121,734 shares of the company’s stock worth $5,533,000 after buying an additional 24,508 shares during the last quarter. GW&K Investment Management LLC raised its position in Neurocrine Biosciences by 27.6% in the second quarter. GW&K Investment Management LLC now owns 85,588 shares of the company’s stock worth $3,890,000 after buying an additional 18,488 shares during the last quarter. American Century Companies Inc. raised its position in Neurocrine Biosciences by 890.6% in the second quarter. American Century Companies Inc. now owns 821,527 shares of the company’s stock worth $37,338,000 after buying an additional 738,598 shares during the last quarter. Moody Aldrich Partners LLC raised its position in Neurocrine Biosciences by 214.8% in the second quarter. Moody Aldrich Partners LLC now owns 30,960 shares of the company’s stock worth $1,407,000 after buying an additional 21,125 shares during the last quarter. Finally, Shell Asset Management Co. acquired a new position in Neurocrine Biosciences during the second quarter worth $496,000. Hedge funds and other institutional investors own 96.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences Inc. (NBIX) Coverage Initiated by Analysts at Citigroup Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States & international copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/23/neurocrine-biosciences-inc-nbix-coverage-initiated-by-analysts-at-citigroup-inc.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.